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Reidar Albrechtsen 5, Bolette Hartmann 1,2, Mette M. Rosenkilde 1, Jens J. Holst 1,2,*ABSTRACT
Objective: Bile acids (BAs) facilitate fat absorption and may play a role in glucose and metabolism regulation, stimulating the secretion of gut
hormones. The relative importance and mechanisms involved in BA-stimulated secretion of appetite and metabolism regulating hormones from
the gut and pancreas is not well described and was the purpose of this study.
Methods: The effects of bile acids on the secretion of gut and pancreatic hormones was studied in rats and compared to the most well described
nutritional secretagogue: glucose. The molecular mechanisms that underlie the secretion was studied by isolated perfused rat and mouse small
intestine and pancreas preparations and supported by immunohistochemistry, expression analysis, and pharmacological studies.
Results: Bile acids robustly stimulate secretion of not only the incretin hormones, glucose-dependent insulinotropic peptide (GIP), and glucagon-
like peptide-1 (GLP-1), but also glucagon and insulin in vivo, to levels comparable to those resulting from glucose stimulation. The mechanisms of
GLP-1, neurotensin, and peptide YY (PYY) secretion was secondary to intestinal absorption and depended on activation of basolateral membrane
Takeda G-protein receptor 5 (TGR5) receptors on the L-cells in the following order of potency: Lithocholic acid (LCA) >Deoxycholicacid (DCA)>
Chenodeoxycholicacid (CDCA)> Cholic acid (CA). Thus BAs did not stimulate secretion of GLP-1 and PYY from perfused small intestine in TGR5 KO
mice but stimulated robust responses in wild type littermates. TGR5 is not expressed on a-cells or b-cells, and BAs had no direct effects on
glucagon or insulin secretion from the perfused pancreas.
Conclusion: BAs should be considered not only as fat emulsiﬁers but also as important regulators of appetite- and metabolism-regulating
hormones by activation of basolateral intestinal TGR5.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The gut is the source of several hormones with important effects on
appetite (neurotensin (NT), glucagon-like peptide-1 (GLP-1), and
polypeptide YY (PYY)) and glucose regulation (the incretin hormones,
glucose-dependent insulinotropic peptide (GIP) and GLP-1) [7,16,29].
Activation of this system, therefore, represents a potential approach to
treat type-2-diabetes and obesity, and this has generated considerable
interest in understanding the molecular sensing mechanisms under-
lying the secretion of these hormones. Recent studies have indicated
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regulating peptide hormones from the gut and pancreas, including
glucagon, GIP, GLP-1 insulin, and PYY
[2,3,6,13,14,19,30,34,35,38,46,47], but the molecular sensing
mechanisms involved are not well understood. The aim of this study
was two-fold. First, we sought to evaluate the rat as a model for BA
effects by examining the effects of BAs on the secretion of the most
important appetite- and metabolism-regulating hormones from the gut
and pancreas: ghrelin, GLP-1, NT, GIP, glucagon, insulin, and PYY and
to compare the secretory responses to those elicited by glucose.
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behind the hormonal responses using a physiologically relevant model.
The project relies on in vivo studies in rats as well as studies involving
isolated, perfused preparations of the mouse and rat small intestine
and the rat pancreas, allowing the secretory mechanisms to be studied
in detail; these studies were supplemented with immunohistochemical
and receptor pharmacology studies.
2. EXPERIMENTAL PROCEDURES
2.1. Chemicals
Test reagents were obtained as speciﬁed in supplementary methods.
2.2. Animal studies
Studies were conducted with permission from the Danish Animal Ex-
periments Inspectorate (2013-15-2934-00833) and the local ethical
committee in accordance with the guidelines of Danish legislation
governing animal experimentation (1987) and the National Institutes of
Health (publication number 85-23).
2.3. Systemic effects of bile-acids in anesthetized rats e intra-
luminal stimulation
Male Wistar rats (w250 g) were obtained from Janvier (Saint Berthevin
Cedex, France) and housed two per cage under standard conditions
with ad libitum access to chow and water and left to acclimatize for at
least one week before the study. Studies were carried out in different
groups of rats on two occasions. On the day of study, rats were fasted
8 h prior to the study (1500 h) with access to water. Rats were
anesthetized by a subcutaneous injection with Hypnorm/midazolam,
then the lower part of the abdominal cavity was opened and a needle
inserted into the inferior vena cava approximately 2 cm cranial to the
iliac veins. A plastic tube was also inserted into the intestinal lumen
approximately 8 cm below the pyloric sphincter. A basal blood sample
was collected 5 min later and another immediately before stimulant
administration. At time 0 min, rats (n ¼ 9) were given 1.5 mL intra-
luminally of one of the following four solutions: 1) a complex bile
acid mixture consisting of CA, GCA, TCA, GDCA, TDCA, DCA, CDCA,
GCDCA, TCDCA; each 0.321 mM, 2) a mixture of UDCA and TUDCA,
each at concentration of 1.404 mM, thus resulting in a similar total bile
acid concentration as the complex bile acid mixture (2.808 mM), 3) D-
glucose (50% (w/v): positive control), or 4) 0.9% NaCl (negative con-
trol). All stimulants were diluted in 0.9% NaCl. Rat body weights did not
differ between treatment groups (3055 g vs. 3043 g, vs. 3004 g
vs. 2955 g, P > 0.05 for all groups), and, on each study occasion,
rats from the same cage received different treatments. Blood for
hormone and blood glucose measurement was collected through the
needle in vena cava (200 mL/time point; 1800 mL in total) into ice cold
EDTA-coated tubes at time 5, 0, 2, 5, 10, and 30 min, and blood
glucose was immediately measured by a handheld glucometer utilizing
the gluco-oxidase method (Accu-chek Compact plus device, Roche,
Mannheim, Germany). Samples for hormone analysis were centrifuged
(1,650  g, 4 C, 10 min) to obtain plasma, which was transferred to
fresh Eppendorf tubes and immediately frozen on dry ice. Samples
were stored at 20 C until analysis. In between sample collection,
the needle was regularly ﬂushed with isotonic salt water (w0.2 ml) to
prevent clot formation. Samples were analyzed as described in the
biochemical measurement section.
2.4. Isolated perfused rat and mouse small intestine and rat
pancreas
Methods are described in more detail in the supplementary methods
and elsewhere [8,9,12,24,44]. Male Wistar rats (w250 g) wereMOLECULAR METABOLISM 11 (2018) 84e95  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comhoused as described above and acclimatized for a least a week.
Heterozygous mice (TGR5þ/) [46] were transferred to University of
Copenhagen and bred to generate both TGR5þ/þ and TGR5/
progeny. Animals were housed under same conditions as the rats.
On the day of experiment, TGR5þ/þ or TGR5/ mice (weight
matched) or Wistar rats were anesthetized, and the abdominal
cavity was opened. The upper half of the small intestine and the
entire large intestine (for small intestine perfusions) or the entire
intestine (for the pancreas perfusions) were carefully removed after
tying off the supplying vasculature. Furthermore, for the pancreas
perfusions, the spleen and stomach were removed, and the kidneys
were excluded from perfusion by tying off the renal arteries. For the
intestinal perfusions, a plastic tube was inserted into the lumen to
allow administration of luminal stimulants. The small intestine (the
distal half and the most proximal part connected to the pancreas) or
the pancreas was perfused vascularly through the upper mesenteric
artery or the abdominal aorta with warm (37 C) modiﬁed Krebs
ringer buffer gassed with 95% O2 and 5% CO2 (both v/v) until
equilibrium, using a Uniper UP-100 perfusion system (Hugo Sachs;
Harvard Apparatus, March-Hugstetten, Germany), and venous
efﬂuent were collected through a catheter in vena portae. As soon
as the catheters were in place, the animals were killed by perfo-
ration of the diaphragm, and the preparation was allowed to
equilibrate for approximately 30 min before sample collection
Venous efﬂuent was collected, immediately chilled on ice, and
transferred to 20 C within 30 min.
2.5. TGR5 expression in isolated murine a-, b-, d- and L-cells
TGR5 expression in L-cell positive and L-cell negative epithelial
cells were isolated from transgenic mice (GLU-Venus) expressing
ﬂuorescent proteins under the control of proglucagon promoter
[36]. Pancreatic a-cells were isolated from GLU-Venus transgenic
mice and pancreatic d-cells from transgenic mice expressing YFP
under the control of the somatostatin promoter as described pre-
viously [1]. The b-cells were isolated on the basis of their size,
using forward and side scatter characteristics distinguishing them
from other nonﬂuorescent islet cells in single cell preparations
from mice with glucagon-driven Venus expression. TGR5 expres-
sion was determined by RT-PCR and expressed relative to beta-
actin as described previously [36] and speciﬁed in supplemen-
tary methods.
2.6. Biochemical measurements
In vivo rat study: Plasma concentrations of peptide hormones were
determined using a customized xMAP based multiplex-assay (Milliplex
map rat metabolic hormone magnetic bead panel e metabolism
multiplex assay, cat. no. RMHMAG-84 K, Millipore), for the following
selected analytes: Amylin (Active), C-Peptide, Ghrelin (Active), GIP
(Total), GLP-1 (total), Glucagon, IL-6, Insulin, Leptin, MCP-1, PP, PYY
(Total), TNF-a. The assay is reported to have no signiﬁcant cross-
reactivity with other hormone tested. After the analytes were bound
to the antibody-coupled beads, a biotinylated detection antibody was
added, followed by incubation with streptavidin-phycoerythrin conju-
gate. Subsequently, the beads were subjected to a ﬂow cytometry-
based detection method using a Luminex laser-based analyzer (cat-
alog no. Luminex 200, Luminex, Austin, TX 78727, USA). The manu-
facturer’s instructions were closely followed. Reported intra- and inter-
assay variation was 1e8% and 7e29%, respectively. The median
ﬂuorescent intensities from the eight calibrators were used to inter-
polate concentrations in plasma samples using 5-parameter logistic
regression.cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 85
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Figure 1: Effects of BAs on the secretion of pancreatic peptide hormones in anesthetized rats. Plasma mean values  SEM are shown. A: Blood glucose, B: Amylin, C:
Glucagon, D: C-peptide, E: Insulin, F: Pancreatic peptide (PP). * Red: Bile acid group, black: glucose group and grey: 0.9% NaCl group (neg. control). n ¼ 9 (bile acid and glucose);
n ¼ 3 (0.9% NaCl). *P < 0.05, **P < 0.01 between respective baseline and response values or between treatment groups (AUCs).
Original Article2.7. Isolated perfused organs
Total bile acid concentrations in venous efﬂuents were measured by
an enzymatic assay relying on the ability of bile acids (in the presence
of 3a-hydroxysteroid dehydrogenase) to reduce thio-NADþ to thio-
NADH (detected) (Total Bile Acid Kit, Cat. no. STA-631, Cell Biolabs
Inc. CA, USA). Peptides from the isolated perfused mouse/rat intes-
tine/pancreas were quantiﬁed by use of extensively validated in-
house radioimmunoassays (RIAs). GLP-1 concentrations were
measured with assay 89390, employing an antibody speciﬁcally
targeting the amidated C-terminus of the molecule, thus measuring
total GLP-1 (both intact GLP-1 7-36amide, the primary metabolite
GLP-1 9-36amide and other potential N-terminally truncated or
extended isoforms) [32]. The amidated isoform of GLP-1 was tar-
geted rather than the glycine extended isoform (GLP-1 7e37)
because the rat predominantly stores and secretes amidated GLP-1
[22,45]. Rat PYY (total) was measured employing antibody T-4093,
measuring both intact 1e36 and the primary metabolite PYY 3e36
[45]. NT (total) was measured using antibody 3D97, which targets N-
terminal epitopes in the 1e8 sequence, thus targeting total NT [23].
Glucagon was measured with the C-terminally directed antibody
4305, which reacts with all bioactive forms of glucagon [31]. Insulin
was measured using antibody 2006 which detects all bioactive forms
of (murine) insulin [5]. Somatostatin was measured with a side-
viewing antibody (assay 1758), thus detecting all bioactive peptide86 MOLECULAR METABOLISM 11 (2018) 84e95  2018 The Authors. Published by Elsevier GmbH. Tforms (SST-14 and SST-28) [17]. For all measurements, standard
curves were prepared in perfusion buffer, which was shown to be
devoid of matrix effects in control studies. Further assay details on
the respective assays, including experimental detection limits, can be
found elsewhere [25].
2.8. TGR5-induced cAMP production
COS-7 cells were grown in DMEM supplemented with 2 mM L-
glutamine, 180 U/ml penicillin, 45 mg/ml streptomycin, and 10% (v/v)
FBS according to protocols described previously [39]. 35,000 COS-7
cells per well were seeded in 96-well plates coated with poly-D-
lysine and modiﬁed for either human or rat TGR5 expression using a
transient calcium phosphate precipitation transfection procedure [21],
using a pCMV6-XL5 or pCMV6-Entry vector, respectively (Cat. no.
SC123312 and RN210451, OriGene, Technologies Inc., Rockville, MD).
On the assay day, two days after transfection, growth medium was
removed from the cells, and they were left to equilibrate in HBS buffer
containing 1 mM IBMX for 30 min at 37 C. Concentrations of different
BAs or the TGR5 agonist RO6272296 were added to duplicate wells,
and the cells were incubated for 30 min at 37 C and subjected to
in vitro HitHunter cAMP assay (based on enzyme fragment comple-
mentation, DiscoveRx) carried out according to the manufacturer’s
instructions. The TGR5 agonist was included in all runs to allow for
data normalization between runs.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
2.9. Immunohistochemistry
Control wild type C57BL/6 male mice and male Wistar rats (w300 g,
Taconic, Ejby, Denmark) were killed and approximately 2 cm of the
jejunum was collected. Tissue samples were ﬁxed in formalin, parafﬁn
embedded, sectioned, and processed using standard methods [51],
The immuno-ﬂuorescence staining protocol employed involved mi-
crowave treatment as previously described [52]. The double immu-
noﬂuorescence staining was performed using (rabbit) anti-GLP-1
(ab22625, Abcam 330 Cambridge Science Park, Cambridge, CB4
0FL, UK) and (goat) anti-TGR5 (Cat. no. SC-48687, Santa Cruz
Biotechnology, Inc. Dallas, TX) diluted 1:50 in 10% (v/v) FBS in PBS.
Sections were incubated overnight at 4 C, washed thoroughly with
PBS, and then double labeled with (donkey) anti-rabbit IgG (H þ L):
Alexa Fluor 546 conjugate (Cat. no. A10040, ThermoFischer Scien-
tiﬁc, Slangerup, Denmark) and (donkey) anti-goat IgG (H þ L): Alexa
Fluor 488 conjugate (Cat. no. A11055, ThermoFischer Scientiﬁc)
after 30 min incubation. Cell nuclei were stained with DAPI (40, 6-
Diamidino-2-phenylindole dihydrochloride). Fluorescence imaging
was performed using a Zeiss confocal 510 microscope equipped with
a water 63x/1.0 Plan-Apochromat objective and Zen software (Carl
Zeiss, Oberkochen, Germany). In a separate set of experiments, the
speciﬁcity of the TGR5 antibody applied above as well as another TGR5
antibody (Cat. no. LS-A1936, LifeSpan BioSciences, Inc., Seattle, WA),
was validated by transfecting HEK293 with cDNA clones containing
mouse or rat (Myc-DKK-tagged) TGR5 transcript (Cat. no. MR227683BA-mix Glu
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Figure 2: Effects of BAs on the secretion of gut-peptide hormones in anesthetized ra
D: Ghrelin, E: Leptin, F: IL-6. Red: Bile acid group, black: glucose group and grey: 0.9% N
**P < 0.01, ***P < 0.001 between respective baseline and response values.
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www.molecularmetabolism.comand RR 210451) or with mock vector. Antibody SC-48687 strongly
reacted with cells transfected with either mouse and rat TGR5 cDNA
(identiﬁed by co-expression of c-Myc), whereas the other TGR5 anti-
body (LS-A1936) did not react with TGR5 transfected cells and were
therefore judged unsuitable for further characterization (data shown in
Supplementary Fig. 1A). To further validate the speciﬁcity of the SC-
48687 antibody, we applied the same protocol as described above
on small intestinal tissue collected from a TGR5 KO mouse or wild type
littermate. Staining was conﬁrmed in the tissue from the wild type
littermate but not the TRG5 KO mouse (Supplementary Fig. 1B). IBAT
staining was performed on the same tissue by similar methods using
an antibody from Aviva Systems Biology (Cat. no. OAEB00210, San
Diego, CA).
2.10. Data presentation and statistical analysis
In vivo data are presented as absolute mean values  SEM and as
baseline-corrected (calculated as the mean of 5 and 0 min con-
centrations) area under the curve (AUC) values to compare overall
effects during the course of the study between treatments. Perfusion
data are presented as absolute mean values  1SEM. TGR5 phar-
macology data are presented normalized to the maximal [cAMP]
response obtained by the TGR5 agonist RO6272296. Statistical sig-
niﬁcance of responses was tested by: In vivo responses: One-way
ANOVA followed by the Tukey post hoc test where appropriate,
either testing the individual time points against each of the stimuli’s0.9% NaClcose
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Figure 3: Bile acid-stimulated GLP-1, NT and PYY secretion depends on intestinal absorption, but electrogenic-absorption through Ileal-bile acid-transporter (IBAT)
does contribute to the response. Data are shown as means  1 SEM. A1-4: Effects of luminal instillation of a complex BA-mix þ/ the bile acid sequestrant cholevelam on GLP-
1, NT and PYY secretion (A.1.2) and bile acid absorption (A.3.4), n¼6. B1-4: Effects of luminal TDCA þ/ luminal IBAT inhibitor on GLP-1, NT, and PYY secretion (B1,2) and TDCA-
absorption (B3,4), n¼6. C1-4: Effects on an un-conjugated BA-mixture (CA, DCA, and CDCA) þ/ IBAT inhibitor on GLP-1, NT, and PYY secretion (C1,2) and BA absorption (C3,4),
n¼6. D: IBAT expression down the rat small intestine, n¼4, E: IBAT and GLP-1 expression in rat intestinal tissue. F1,2: Effects of TDCA þ/ nifedipine (a voltage-gated calcium-
channel blocker) on GLP-1, NT, and PYY secretion, n¼6. G1,2: Effects of luminal TDCA on GLP-1 and PYY secretion (control experiment), n ¼ 6. In all perfusion experiments,
bombesin (BBS) was administered in the end of the experiment and used as positive control. */#P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Figure 4: Bile acids stimulate GLP-1, NT, and PYY secretion by activation of basolateral, but not luminal, TGR5 receptors. Data are shown as means  1 SEM. All X-Y plot
data with exception of C, D, F, I and J are from isolated perfused rat small intestine. A1,2: Effects of luminal and vascular administration of a poorly absorbable TGR5 agonist on
GLP-1, NT and PYY secretion, n¼6. B1,2: Effects of luminal and vascular administration of GW4064 (a FXR agonist) on GLP-1, NT and PYY secretion, n¼6. C,D: Activation of TGR5
in response to different bile-acids in cells transfected with either the human TGR5 receptor (C) or rat TGR5 receptor (D). E: Co-localization of TGR5 and GLP-1/PYY in rat small
intestine. F: Expression of TGR5 in isolated pancreatic a-, b- or d-cells or intestinal L-cells from the mouse, n¼3. G: Plasma GLP-1 (total) concentrations in response to a complex
BA-mix (n¼6), match total conc. of UDCA (n¼8) or 0.9%NaCl (neg. control, n ¼ 3). H1,2: Effects of vascular TUDCA, TCDCA or TDCA on GLP-1, NT and PYY secretion, n¼6. I and
J: Effects of a complex BA-mix on the secretion of GLP-1 and PYY from isolated perfused mouse small intestine. I: WT mice, J: TGR5 KO mice, n ¼ 6. In all perfusion experiments,
bombesin (BBS) was administered in the end of the experiment and used as positive control. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Original Articleown baseline (average of 5 and 0 min) or testing AUCs against each
other. Perfusion responses were assessed by comparing averaged
concentrations during the stimulation period (10 consecutive 1-min
observations) with mean basal levels over a similar duration: imme-
diately before the stimulation (5 consecutive 1-min observations) and
at the end of the following equilibrium period (also 5 consecutive 1-min
observations). Signiﬁcance was assessed by One-way-ANOVA fol-
lowed by Tukey post hoc. For the remaining data, unpaired or paired
two-sided t-test was used to assess differences between two groups,
as indicated. For all tests, threshold for signiﬁcance was set to
P ¼ 0.05.
3. RESULTS
3.1. Intra-luminal delivery of bile acids stimulates secretion of
numerous appetite- and metabolism-regulating peptides in
anesthetized rats
Blood glucose was unaltered by an intra-luminally administered BA-
mix (cholic acid (CA), deoxycholic acid (DCA) and chenodeoxycholic
acid (CDCA) both in free form and in their glycine- and taurine-
conjugated forms, 1 mM each) (P > 0.05, Figure 1A) but increased
after intra-luminal glucose treatment (baseline: 9.6  0.2 mM, peak:
15.5  1.2, P < 0.001). Glucose as well as the BA-mix stimulated
amylin secretion 15 and 30 min after administration (P < 0.05,
Figure 1B). Glucagon secretion increased after BA-mix administration
at time point 5 min (P < 0.05, Figure 1.C1) and net AUC0e15min
increased (PNaCl vs. BA-mix ¼ 0.07, Figure 1.C2). Both glucose and BAs
stimulated plasma C-peptide and insulin secretion at the later time
points (Figure 1.D,E). GIP and GLP-1 secretion was robustly stimulated
by the bile acid mix (2e4 fold) at 5 min (P < 0.05 compared to
baseline, n ¼ 9 Figure 2A,B) and returned to baseline at 15 min.
Similar responses were observed after intra-duodenal glucose,
and neither peak-value nor AUCs differed between treatments
(PGIP, glucose vs. BA-mix AUC’s¼ 0.78, PGLP-1, glucose vs. BA-mix AUC’s¼ 0.77,
n ¼ 9, Figure 2A,B). Glucose and BAs both tended to increase PYY
secretion (Figure 2C). For all measured peptides, plasma concentra-
tions remained unchanged at all time points in the isotonic saline
control group (P > 0.05, Figures 1 and 2).
3.2. Molecular mechanisms of bile-acid stimulated secretion of
GLP-1, NT and PYY
3.2.1. Effects of bile acids and a bile acid sequestrant
Since GLP-1 and PYY secretion was stimulated by BAs in vivo, we next
investigated the molecular mechanisms underlying these (as well as
NT) responses using the isolated, perfused rat small intestine. Intra-
luminal instillation of a BA mixture (CA, DCA, CDCA in both un-
conjugated and glycine- and taurine-conjugated forms) increased
secretion of GLP-1, PYY and NT to 4e8 times the basal secretion, and
this was prevented by cholesevelam (Figure 3.A1e2, n ¼ 6). Cho-
lesevelam is a BA sequestrant, which binds to BAs and reduces their
absorption (Figure 3A3e4). In order to investigate whether the lack of
gut hormone secretion in the presence of this BA-sequestrant
(Figure 3A1e2) was due to reduced availability of free BAs to stimu-
late luminally exposed receptors or to reduced absorption and reduced
exposure of basolateral BA (Figure 3D,G), we next tested the effects of
inhibiting the predominant transporter for conjugated bile acids, the
ileal-bile acid transporter (IBAT).
3.2.2. Role of the ileal-bile acid transporter (IBAT)
Transporter inhibition attenuated both TDCA absorption and hormone
secretion (Figure 3 B1e4, n¼6). In a separate line of experiments, we90 MOLECULAR METABOLISM 11 (2018) 84e95  2018 The Authors. Published by Elsevier GmbH. Ttested the effect of the IBAT inhibitor together with intra-luminal
infusion of a mixture of unconjugated BAs (CA, DCA, and CDCA:
each 1 mM), which are more lipophilic than the conjugated-BAs (and
should, therefore, be absorbed by IBAT-independent diffusion over the
intestinal epithelium). In this case, the inhibitor had no effects on either
the BA absorption or the GLP-1 and NT responses, (although PYY
secretion was slightly reduced) (P < 0.01, Figure 3.C1e4, n¼6). As
IBAT couples BA uptake to the co-uptake of sodium, activity of this
transporter could (if present on the respective enteroendocrine cells),
in itself stimulate peptide secretion by depolarizing the L-cell, as is the
case for glucose-stimulated GLP-1 and NT secretion (through the
sodium-glucose transporter 1 [11,22e24,33,37]). In the rat, IBAT was
predominately expressed in the ileum (Figure 3D) and co-localized with
GLP-1 (Figure 3E), but the effect of IBAT activity on TDCA-stimulated
GLP-1, NT, or PYY secretion from the perfused rat intestine does not
appear to involve cell depolarization since inhibition of L-type voltage-
gated calcium channels (by nifedipine) had no effect on the secretory
response (Figure 3F.1,2). In separate control studies, intra-luminal
administration of TDCA robustly stimulated the secretion of GLP-1,
NT, and PYY and in case of GLP-1 and NT to a comparable extent
when applied twice in the same experiment (Figure 3 F1, 2, n ¼ 6),
conﬁrming that the attenuation of TDCA-stimulated secretion in
presence of the IBAT inhibitor was a speciﬁc event.
3.2.3. The role of farnesoid-X-activated receptor or G protein-
coupled bile acid receptor 1 (GPBAR1/TGR5)
We next investigated whether the secretory response to BAs could be
explained by activation of the BA-sensitive receptors FXR or TGR5.
Intra-arterial, but not intra-luminal, application of a poorly absorbable
TGR5 agonist [48] robustly stimulated GLP-1, NT and PYY secretion
(Figure 4A.1,2), while application of a speciﬁc FXR agonist had no
effect whether applied from the luminal or vascular route
(Figure 4B1,2). In COS-7 cells transiently transfected with either the
human or rat TGR5 (Figure 4C,D), a strong activating signal was
observed with pharmacologically relevant BA doses (EC50 < 1 mM) in
following order of potency: LCA > DCA > CDCA acid for both re-
ceptors. Comparable efﬁcacy and potency were observed for free,
taurine- and glycine-conjugated forms of the respective BAs. In
contrast, UDCA (free or taurine- and glycine-conjugated) did not acti-
vate human or rat TGR5 in concentrations up to 10 mM, while CA (free
as well as glycine- and taurine-conjugated forms) was a weak agonist
for the rat but not the human receptor (Figure 4C1e5, D1e5). Addi-
tional pharmacological properties of the tested BAs (Hill slope, time to
peak, EC50-value and percentage efﬁcacy compared to maximal
cAMP-response resulting from TGR5-agonist stimulation) are provided
in Supplementary Table 1. As we found TGR5 to be expressed by
isolated primary mouse L-cells and to co-localize with GLP-1 and PYY
in rat small intestine (Figure 4E,F), our data, therefore, indicate that BA-
stimulated secretion is dependent on direct activation of basolaterally
located TGR5 receptors expressed by the N- or L-cell. Intra-luminal
UDCA (which does not activate TGR5) in vivo did not change GLP-1
secretion, whereas a complex BA mixture (CA, DCA, and CDCA in
un-conjugated and glycine- and taurine-conjugated forms) with the
same total BA concentration resulted in a pronounced increase
(Figure 4G). Furthermore, intra-arterial TUDCA (0.01 mM) neither
stimulated GLP-1, NT nor PYY secretion from isolated perfused rat
small intestine, in contrast to the TGR5-activating BAs TCDCA and
TDCA, both of which robustly stimulated secretion when applied at the
same concentration (P < 0.001, n ¼ 6, Figure 4H1,2. To further
demonstrate the role of the TGR5 receptor, we also studied isolated
perfused small intestine from TGR5 knockout (KO) mice [46]. Here,his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: TGR5 activation or bile acids has no direct effects on glucagon or insulin secretion. Data are shown as means ? 1 SEM. All data are from isolated perfused rat
pancreas. A. Glucagon (1,2) and insulin (3,4) secretion at low glucose (3.5 mmol/L) in response to the TGR5 agonist RO9272296 or a complex BA-mix. B: Glucagon (1,2) and insulin
(3,4) secretion at high glucose (10 mmol/L) in response to the TGR5 agonist RO9272296 or a complex BA-mix. L-arginine (Arg) was included at the end of all experiment and used
a positive control. n ¼ 6 for all experiments. *P < 0.05, **/##P < 0.01, ***/###P < 0.001, ****P < 0.0001. Stars indicate signiﬁcance compared to baseline and hashes indicate
signiﬁcance between treatments.intra-luminal administration of bile acids (same complex mixture as
above) had no effects on GLP-1 and PYY secretion, whereas a robust
hormone response was seen in wild-type littermates (Figure 4I,J).
3.3. No direct effects of bile acids on the secretion of pancreatic
hormones
To investigate whether the BA-stimulated insulin response and the
tendency to stimulated glucagon secretion observed in vivo resulted
from direct effects of BAs on the pancreas, we studied the direct ef-
fects of BAs and direct TGR5 activation in the isolated perfused rat
pancreas, using the same BA-mix and TGR5 agonist used in vivo and in
the intestine perfusions. Neither BAs nor the TGR5 agonist (even at a
10-fold higher dose than that which robustly stimulated GLP-1, NT and
PYY secretion in the gut) had any effect on glucagon or insulin
secretion, whether at low (3.5 mM) or high (10 mM) glucose levels
(Figure 5AeD). consistent with our observation that neither pancreatic
a- nor b-cells isolated from mice express TGR5 (Figure 4F). Glucose
had the expected effects on the secretion of these peptides: raising the
glucose concentration from 3.5 to 10 mM inhibited glucagon secretion
by a factor of approx. 15 and stimulated insulin secretion by a factor of
approx. 10, while L-arginine (pos. control) also robustly stimulated the
secretion of both hormones.
4. DISCUSSION
In humans, BAs have been identiﬁed as stimuli for glucagon, GLP-1,
insulin, NT, and PYY secretion [2,3,13,30,38], but a detailed analysis
of the physiological sensing mechanisms involved has not been carried
out, and this was the purpose of our study. Because of their chemical
nature, unspeciﬁc effects of BAs could potentially confound interpre-
tation of results, especially when used in high concentrations. Since
such studies cannot easily be carried out in humans, we turned to rats
and ﬁrst investigated the effects of intraluminal BA stimulation (a
complex mixture) on a number of appetite- and metabolism-regulatingMOLECULAR METABOLISM 11 (2018) 84e95  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.compeptide hormones in anesthetized animals. The BAs were administered
in a dose similar to that reached intra-luminally in the proximal small
intestine in humans after meal intake, i.e. 4e12mMdepending onmeal
composition [41,49] and well above the critical micellar concentration
1e2 mM [15]. However, whether the composition of the applied BA mix
in our study is representative for the postprandial intraluminal compo-
sition in humans (or rats) is difﬁcult to assess. This is because most data
on the composition of BAs in humans have been collected from samples
obtained from a peripheral vein. Little is known about how closely this
reﬂects the composition of BAs originally secreted into the intestinal
lumen, because intestinal reabsorption and liver retention may differ
between BAs and because of differences in the microbial activity in the
gut which dehydroxylates the primary Bas. In the anesthetized rat, intra-
luminal administration of the complex BA-mix (9 mM in total) robustly
stimulated the secretion of GIP, GLP-1, C-peptide and insulin, mirroring
the effects of BAs in humans [2,3,13,38]. Remarkably, the secretory
responses were of comparable magnitude to those resulting from intra-
luminal glucose administration (a powerful stimulus for most of these
peptides [18]). For PYY, the half hour sample collection period may have
been too short to allow the stimulants to reach all of the more distally
located PYY.
To study the secretory pathways directly involved in BA-stimulated gut
hormone secretion, we used the isolated perfused rodent small in-
testine. The beneﬁt of this model is that it allows a high level of
experimental control (e.g. it is possible to discriminate between re-
sponses caused by luminal or vascular activation of secretory sensors),
high time resolution (secretion is followed minute by minute), and
application of drugs that may have been hazardous or lethal in vivo, as
reviewed [43]. Additionally, the natural anatomical arrangement of the
cells (including polarization) and the vascular perfusion (and therefore
convective drag of absorbed nutrients and secreted hormones) are
preserved [43], allowing studies of the full dynamics of absorption and
secretion. Thus, conclusions drawn from results obtained using this
model are likely to be physiologically relevant.cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 91
Figure 6: Proposed model of bile acid stimulated secretion of appetite and metabolism regulating hormones. (1) Food intake, and in particular fat consumption, stimulates
the secretion of bile acids into the upper small intestine by CCK-mediated contraction of the gallbladder. (2) In addition to their well-known role in facilitating fat absorption (by
micelle formation) bile acids activate TGR5 receptors which are located at the basolateral membranes of the enterocytes and therefore are activated secondary to bile acid (BA)
absorption. Upon activation, the secretion of GIP, GLP-1, NT, and PYY is stimulated. Conjugated bile acids are absorbed through the secondary active transporter ileal-bile acid
transporter (IBAT) which is predominantly expressed in the lower part of the small intestine, whereas unconjugated bile acids (which are more lipophilic) spontaneously cross the
intestinal mucosal layer. (3) Eliminating bile acid absorption by BA-sequestrants (which cross bind both conjugated and unconjugated BAs into large unabsorbable complexes) or by
direct IBAT inhibition (which attenuates the absorption of conjugated BAs) therefore eliminates BA-stimulated gut hormone secretion. (4) Collectively, the absorption mechanisms
results in a very efﬁcient BA absorption so about 95% of the secreted bile acids are returned to the liver through the enterohepatic circulation. (5) The majority of the returned bile
acids are extracted by the liver (where they are reconjugated and rehydroxylated, allowing the same pool of bile acids to be secreted several times during the day), (6) Only 3e10%
pass the liver and eventually ends up in the systemic circulation, (7) The pool is further diluted with a factor of about three since the hepatic return constitutes about 1/3 of the total
venous return. (8) Therefore, only a small fraction of the secreted bile acid makes it to the systemic circulation.
Original ArticleSimilar to the in vivo study, intra-luminal BA administration resulted in
robust GLP-1, NT, and PYY responses, conﬁrming in vitro studies
where a variety of BAs have been shown to stimulate GLP-1 secretion
from the GLP-1 producing cell lines GLUTag and STC-1, from primary
murine cell cultures, and from mouse gut tissue mounted in Ussing
chambers [6,19,34]. In our perfused gut model, we are able to
demonstrate that peptide secretion depends on the absorption of BAs,
since BA-sequestrants (cholesevelam) or pharmacological inhibition of
the transporter responsible for conjugated BA uptake from the intes-
tinal lumen, IBAT, eliminated the secretory responses. In contrast, the92 MOLECULAR METABOLISM 11 (2018) 84e95  2018 The Authors. Published by Elsevier GmbH. Tsecretory responses to a mixture of unconjugated BAs (which are
absorbed by IBAT-independent diffusion over the intestinal epithelium)
were unaffected by IBAT inhibition. Consistent with this, IBAT inhibition
attenuated conjugated BAs stimulated GLP-1 secretion from mouse
epithelium mounted in Ussing chambers [6]. Although L-cells have
been shown to express IBAT [6] and we here demonstrate co-
localization (by immunohistochemistry) of this transporter with GLP-
1, the secretory response to luminal (conjugated) BAs did not appear
to depend on cellular depolarization resulting from coupled sodium
transport, since inhibition of voltage-gated calcium channels (byhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nifedipine) had no effect on the secretory response to conjugated BAs
(whereas the same dose of nifedipine has been shown to eliminate
glucose-stimulated GLP-1 and NT secretion [23,24]). This is consistent
with our previous observation with regards to BA-stimulated GLP-1
secretion from mouse gut tissue mounted in Ussing chambers [6]. We
therefore next investigated whether stimulated secretion relied on
activation of BA-sensitive receptors. BAs have previously [6,46] been
shown to activate the surface receptor TGR5 [20] and the nuclear
receptor FXR, with the latter being effectively activated by CDCA, TCA,
TCDCA, TDCA (but not tauro-muricholic acid) [28,50]. In our perfused
rat intestine model, application of a speciﬁc FXR-agonist (GW4064)
from the luminal or vascular side (at concentrations far above the
reported EC50 of 15 nM [4]) had no effect on peptide secretion, indi-
cating that activation of FXR is not acutely involved in the secretory
response. Rather, this nuclear receptor may play a role for the bene-
ﬁcial (transcriptional) adaptations resulting from gastric bypass oper-
ations in mice [40]. In contrast, administration of a poorly-absorbable
TGR5 agonist [48] to the perfused rat intestine from the vascular, but
not the luminal, side of the preparation robustly stimulated the
secretion of GLP-1, NT, and PYY. This is consistent with a study by
Ullmer C et al. who showed that systemic rather than luminal activation
of TGR5 stimulated GLP-1 and PYY secretion in mice, since intravenous
but not oral administration of the same TGR5 agonist used here
stimulated secretion [48]. By immunohistochemical and pharmaco-
logical studies, we showed that BAs appear to stimulate secretion of
these peptides by direct activation of TGR5 at the level on the L-cell,
because the receptor is co-localized with GLP-1 on the basolateral side
of the cell and is activated (both human and rat versions of the re-
ceptor) by a variety of BAs in the following order of potency:
LA > DCA > CDCA, irrespectively of conjugation. Consistent with this,
UDCA and its glycine- and taurine-conjugated isoforms neither acti-
vated the receptor nor stimulated GLP-1 secretion. Since a TGR5
antagonist, which could provide further evidence for the role of this
receptor is not available, we used TGR5 KO mice [46] and wild type
littermates for gut perfusion studies [12]. In line with our observations
from the rat and two studies using other experimental models [6,46],
TGR5 deﬁciency resulted in elimination of BA-stimulated GLP-1 and
PYY secretion.
BAs or selective TGR5 agonists have been suggested to directly
stimulate glucagon and insulin secretion from isolated human and
rodent islets [10,26,27]. However, although we observed stimulatory
effects of BAs on insulin secretion in vivo, these seemed to be indirect,
as the same complex BA-mixture that gave rise to robust secretion of
gut hormones had no effect on secretion of glucagon or insulin from
the perfused rat pancreas. Furthermore, TGR5 was not expressed in
primary a- or b-cells and a TGR5 agonist (which stimulated secretion
of GLP-1, NT, and PYY from the perfused intestine) had no effect on
endocrine hormone secretion from the perfused pancreas. Therefore,
the late increase in insulin secretion could be a result of BA-stimulated
secretion of GIP and GLP-1, which could be tested in experiments
involving blockade of the relevant hormone receptors (with GIP and
GLP-1 receptor antagonists, e.g. the truncated GIP isoform 3-30NH2
recently showed to be a competitive antagonist for the rat GIP receptor
[42] and the widely used GLP-1 receptor antagonist, exendin 9-39).
In contrast, glucagon and insulin secretion was very sensitive to changes
in the glucose concentration in the perfusate and responded to our
positive control (L-arginine), conﬁrming that the preparation was func-
tional and responds appropriately to physiological stimuli. BA-stimulated
secretion of insulin, therefore, appears to be mediated indirectly and,
although this remains to be clariﬁed, potential mediators could include
GIP, GLP-1, ﬁbroblast growth factor (FGF19/and/or 21). It thereforeMOLECULAR METABOLISM 11 (2018) 84e95  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comappears that BAs stimulate the secretion of a number of gut hormones
by activation of TGR5 located on the basolateral side of the enterocytes,
whereas the effects of BAs on glucagon and insulin secretion is indirect.
A detailed model for the molecular mechanisms underlying BA-
stimulated secretion of gut hormones is provided in Figure 6.
5. CONCLUSION
Our study shows that BAs that activate TGR5 have marked effects on
the secretion of appetite and metabolism-regulating hormones and,
therefore, in addition to their role as fat emulsiﬁers, should be regarded
as important regulators of blood glucose and metabolism. Given the
strong stimulatory effect on GIP, GLP-1, NT, and PYY secretion, the
mechanisms of BA-stimulated secretion, here demonstrated to depend
on absorption and TGR5 activation, may represent appealing targets
for development of drugs for treatment of obesity and type-2-diabetes.
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